Chief Legal Officer — David McAvoy: The filing discloses the appointment of a new Chief Legal Officer and Corporate Secretary, with the previous General Counsel retaining a senior role, indicating an internal succession or role expansion rather than a departure.

and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Director — Heath Lukatch: Dr. Heath Lukatch retired from the Board, and John Markels was appointed as a new director.

Director — Jacks Lee: Mr. Jacks Lee retired from the Board and was succeeded by Dr. Moncef Slaoui.

and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Other Events. Sales Agreement On February 24, 2026, Vaxcyte, Inc. (“ Vaxcyte ”) entered into a sales agreement (the “ Sales Agreement ”) with Leerink Partners LLC (the “ Placement Agent ”), pursuant to which the Company may sell shares of its common stock, par value $0.001 per share (“ Common Stock ”), having an aggregate offering price of up to $500,000,000 (the “ Shares ”), from time to time through the Placement Agent. The Shares are registered with the Securities and Exchange Commission (…

Other Events Underwriting Agreement On January 29, 2026, Vaxcyte, Inc. (“ Vaxcyte ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with BofA Securities, Inc., Jefferies LLC, Leerink Partners LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale (the “ Offering ”) of 11,000,000 shares of its common stock, par value $0.001 per share, at a price to the public of…

Amendments to existing severance agreements were made to better align with peer group levels.

and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. On September 24, 2025 (the “Effective Date”), Vaxcyte, Inc. (the “Company”) entered into a Master Services Agreement (the “Agreement”) with Patheon Manufacturing Services LLC (“Patheon”), part of Thermo Fisher Scientific. Under the Agreement, Patheon will formulate, fill, inspect, package, label, test, manufacture and supply drug product for the Company at Patheon’s facility in Greenville, North Carolina. Pursuant to the Agreement, the Company has a…

and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Director — Dr. Olivier Brandicourt: Dr. Olivier Brandicourt was appointed as a Class III director of Vaxcyte, Inc.

and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. As previously disclosed, Vaxcyte, Inc. (the “ Company ”) entered into (i) a lease agreement (the “ Original Lease ”), dated January 21, 2021, as amended on October 17, 2023, with ARE-San Francisco No. 63, LLC (the “ Landlord ”) for the purpose of establishing the Company’s corporate headquarters at 825 Industrial Road in San Carlos, California (the “ Building ”), and (ii) an assignment and assumption of lease agreement (the “ Assumed Lease ”), dated…

and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Other Events Underwriting Agreement On September 4, 2024, Vaxcyte, Inc. (“ Vaxcyte ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with BofA Securities, Inc., Jefferies LLC, Leerink Partners LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale (the “ Offering ”) of 10,194,175 shares of its common stock, par value $0.001 per share, at…

and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Director — John P. Furey: John P. Furey was appointed as a Class II director and to the Compensation Committee.

and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Other Events Underwriting Agreement On January 30, 2024, Vaxcyte, Inc. (“ Vaxcyte ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with BofA Securities, Inc., Jefferies LLC, Leerink Partners LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale (the “ Offering ”) of 10,937,500 shares of its common stock, par value $0.001 per share, at a price to the public of…

Director — Jacks Lee: Appointment of Jacks Lee as a Class II director and member of the Audit Committee.

Entry into a Material Definitive Agreement. As disclosed in a Form 8-K filed December 20, 2022, on December 19, 2022, Vaxcyte, Inc. (“Vaxcyte”) entered into an option grant agreement (the “Option Agreement”) with Sutro Biopharma, Inc. (“Sutro,” and together with Vaxcyte, the “Companies”), pursuant to which Vaxcyte acquired from Sutro (i) authorization to enter into an agreement with an independent alternate contract manufacturing organization (“CMO”) to directly source Sutro’s cell-free extra…